GLP-1

News

Business Group on Health statistics graphic

As drug costs for US employers rise, some cut GLP-1s from pl...

Pharmacy now represents 25% of employer healthcare spending, and employers are turning to DTC models and non-traditional PBMs to cut costs.

News

Lilly sues over 'illegal sales' of obesity drug retatrutide

Eli Lilly has sued six US-based companies it accuses of participating in an illegal black market for experimental weight-loss drug retatrutide.

News

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

A Dutch compounding pharmacy has been ordered to stop distributing a compounded nasal spray version of Novo Nordisk's GLP-1 agonist semaglutide.

News

A man drunken on vodka lies in the grass

Altimmune alcohol use disorder drug hits the mark in phase 2

Altimmune's pemvidutide has been shown to reduce drinking in people with alcohol use disorder, adding to the evidence for GLP-1 drugs in this setting.

News

Lilly plans Q1 2027 filing for obesity triple retatrutide

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

News

Novo's Wegovy pill cleared for weight loss in EU

The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly.

As drug costs for US employers rise, some cut GLP-1s from pl...

Lilly sues over 'illegal sales' of obesity drug retatrutide

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

Altimmune alcohol use disorder drug hits the mark in phase 2

Lilly plans Q1 2027 filing for obesity triple retatrutide

Novo's Wegovy pill cleared for weight loss in EU

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

GLP-1

Editor's Picks